Patent · US Active

Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease

US8193200B2 · kind B2 · utility

2Cited by

9References

2Claims

0Family size

Assignees

University of Virginia Patent Foundation · US
EMORY UNIVERSITY · US

Inventors

Shanthi V. Sitaraman · Atlanta, US
Joel M. Linden · Charlottesville, US
Guoquan Wang · Charlottesville, US
Robert D. Thompson · Charlottesville, US
Jayson M. Rieger · Charlottesville, US

Key dates

Filing date	Nov 5, 2007
Grant date	Jun 5, 2012
Priority date	—
Expiry date	Dec 12, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P1/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of A2B adenosine receptors (ARs).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.